世界のI型高リポタンパク血症薬市場 2019年

【英語タイトル】Global Type I Hyperlipoproteinemia Drug Market Professional Survey Report 2019

QYResearchが出版した調査資料(DATA908B04842)・商品コード:DATA908B04842
・発行会社(調査会社):QYResearch
・発行日:2019年9月6日
・ページ数:100
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医薬品・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥367,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥735,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートは、I型高リポタンパク血症薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、アリポジーン・チパルボベック、CAT-2003、ISIS-APOCIIIRx、メシル酸ロミタピド、プラジガスタットナトリウム、その他に、用途別には、病院、診療所、その他にセグメント区分し、I型高リポタンパク血症薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・I型高リポタンパク血症薬の世界市場概要
・I型高リポタンパク血症薬の製造コスト構成分析
・I型高リポタンパク血症薬の開発・製造工場分析
・主要メーカーの主な指標(生産能力、売上、価格分析)
・I型高リポタンパク血症薬の地域別分析(生産、売上、主要メーカー、輸出・輸入)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・I型高リポタンパク血症薬のセグメント分析(種類別)
(アリポジーン・チパルボベック、CAT-2003、ISIS-APOCIIIRx、メシル酸ロミタピド、プラジガスタットナトリウム、その他)
・I型高リポタンパク血症薬のセグメント分析(用途別)
(病院、診療所、その他)
・I型高リポタンパク血症薬の主要メーカー別分析(生産拠点、製品概要、生産・売上実績)
(Aegerion Pharmaceuticals, Inc.、Catabasis Pharmaceuticals, Inc.、Isis Pharmaceuticals, Inc.、Novartis AG、uniQure N.V.)
・I型高リポタンパク血症薬の市場規模予測(2019年~2025年)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス(市場動向、機会、成長要因、課題、影響因子)
...
【レポートの概要】

The global Type I Hyperlipoproteinemia Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Type I Hyperlipoproteinemia Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Type I Hyperlipoproteinemia Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Type I Hyperlipoproteinemia Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Type I Hyperlipoproteinemia Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Aegerion Pharmaceuticals, Inc.
Catabasis Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Novartis AG
uniQure N.V.

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Alipogene Tiparvovec
CAT-2003
ISIS-APOCIIIRx
Lomitapide Mesylate
Pradigastat Sodium
Others

Segment by Application
Hospital
Clinic
Others

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Type I Hyperlipoproteinemia Drug
1.1 Definition of Type I Hyperlipoproteinemia Drug
1.2 Type I Hyperlipoproteinemia Drug Segment by Type
1.2.1 Global Type I Hyperlipoproteinemia Drug Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Alipogene Tiparvovec
1.2.3 CAT-2003
1.2.4 ISIS-APOCIIIRx
1.2.5 Lomitapide Mesylate
1.2.6 Pradigastat Sodium
1.2.7 Others
1.3 Type I Hyperlipoproteinemia Drug Segment by Applications
1.3.1 Global Type I Hyperlipoproteinemia Drug Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Type I Hyperlipoproteinemia Drug Overall Market
1.4.1 Global Type I Hyperlipoproteinemia Drug Revenue (2014-2025)
1.4.2 Global Type I Hyperlipoproteinemia Drug Production (2014-2025)
1.4.3 North America Type I Hyperlipoproteinemia Drug Status and Prospect (2014-2025)
1.4.4 Europe Type I Hyperlipoproteinemia Drug Status and Prospect (2014-2025)
1.4.5 China Type I Hyperlipoproteinemia Drug Status and Prospect (2014-2025)
1.4.6 Japan Type I Hyperlipoproteinemia Drug Status and Prospect (2014-2025)
1.4.7 Southeast Asia Type I Hyperlipoproteinemia Drug Status and Prospect (2014-2025)
1.4.8 India Type I Hyperlipoproteinemia Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Type I Hyperlipoproteinemia Drug
2.3 Manufacturing Process Analysis of Type I Hyperlipoproteinemia Drug
2.4 Industry Chain Structure of Type I Hyperlipoproteinemia Drug

3 Development and Manufacturing Plants Analysis of Type I Hyperlipoproteinemia Drug
3.1 Capacity and Commercial Production Date
3.2 Global Type I Hyperlipoproteinemia Drug Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Type I Hyperlipoproteinemia Drug
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Type I Hyperlipoproteinemia Drug Production and Capacity Analysis
4.2 Type I Hyperlipoproteinemia Drug Revenue Analysis
4.3 Type I Hyperlipoproteinemia Drug Price Analysis
4.4 Market Concentration Degree

5 Type I Hyperlipoproteinemia Drug Regional Market Analysis
5.1 Type I Hyperlipoproteinemia Drug Production by Regions
5.1.1 Global Type I Hyperlipoproteinemia Drug Production by Regions
5.1.2 Global Type I Hyperlipoproteinemia Drug Revenue by Regions
5.2 Type I Hyperlipoproteinemia Drug Consumption by Regions
5.3 North America Type I Hyperlipoproteinemia Drug Market Analysis
5.3.1 North America Type I Hyperlipoproteinemia Drug Production
5.3.2 North America Type I Hyperlipoproteinemia Drug Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Type I Hyperlipoproteinemia Drug Import and Export
5.4 Europe Type I Hyperlipoproteinemia Drug Market Analysis
5.4.1 Europe Type I Hyperlipoproteinemia Drug Production
5.4.2 Europe Type I Hyperlipoproteinemia Drug Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Type I Hyperlipoproteinemia Drug Import and Export
5.5 China Type I Hyperlipoproteinemia Drug Market Analysis
5.5.1 China Type I Hyperlipoproteinemia Drug Production
5.5.2 China Type I Hyperlipoproteinemia Drug Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Type I Hyperlipoproteinemia Drug Import and Export
5.6 Japan Type I Hyperlipoproteinemia Drug Market Analysis
5.6.1 Japan Type I Hyperlipoproteinemia Drug Production
5.6.2 Japan Type I Hyperlipoproteinemia Drug Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Type I Hyperlipoproteinemia Drug Import and Export
5.7 Southeast Asia Type I Hyperlipoproteinemia Drug Market Analysis
5.7.1 Southeast Asia Type I Hyperlipoproteinemia Drug Production
5.7.2 Southeast Asia Type I Hyperlipoproteinemia Drug Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Type I Hyperlipoproteinemia Drug Import and Export
5.8 India Type I Hyperlipoproteinemia Drug Market Analysis
5.8.1 India Type I Hyperlipoproteinemia Drug Production
5.8.2 India Type I Hyperlipoproteinemia Drug Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Type I Hyperlipoproteinemia Drug Import and Export

6 Type I Hyperlipoproteinemia Drug Segment Market Analysis (by Type)
6.1 Global Type I Hyperlipoproteinemia Drug Production by Type
6.2 Global Type I Hyperlipoproteinemia Drug Revenue by Type
6.3 Type I Hyperlipoproteinemia Drug Price by Type

7 Type I Hyperlipoproteinemia Drug Segment Market Analysis (by Application)
7.1 Global Type I Hyperlipoproteinemia Drug Consumption by Application
7.2 Global Type I Hyperlipoproteinemia Drug Consumption Market Share by Application (2014-2019)

8 Type I Hyperlipoproteinemia Drug Major Manufacturers Analysis
8.1 Aegerion Pharmaceuticals, Inc.
8.1.1 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
8.1.2 Aegerion Pharmaceuticals, Inc. Product Introduction, Application and Specification
8.1.3 Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Catabasis Pharmaceuticals, Inc.
8.2.1 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
8.2.2 Catabasis Pharmaceuticals, Inc. Product Introduction, Application and Specification
8.2.3 Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Isis Pharmaceuticals, Inc.
8.3.1 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
8.3.2 Isis Pharmaceuticals, Inc. Product Introduction, Application and Specification
8.3.3 Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Novartis AG
8.4.1 Novartis AG Type I Hyperlipoproteinemia Drug Production Sites and Area Served
8.4.2 Novartis AG Product Introduction, Application and Specification
8.4.3 Novartis AG Type I Hyperlipoproteinemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 uniQure N.V.
8.5.1 uniQure N.V. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
8.5.2 uniQure N.V. Product Introduction, Application and Specification
8.5.3 uniQure N.V. Type I Hyperlipoproteinemia Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served

9 Development Trend of Analysis of Type I Hyperlipoproteinemia Drug Market
9.1 Global Type I Hyperlipoproteinemia Drug Market Trend Analysis
9.1.1 Global Type I Hyperlipoproteinemia Drug Market Size (Volume and Value) Forecast 2019-2025
9.2 Type I Hyperlipoproteinemia Drug Regional Market Trend
9.2.1 North America Type I Hyperlipoproteinemia Drug Forecast 2019-2025
9.2.2 Europe Type I Hyperlipoproteinemia Drug Forecast 2019-2025
9.2.3 China Type I Hyperlipoproteinemia Drug Forecast 2019-2025
9.2.4 Japan Type I Hyperlipoproteinemia Drug Forecast 2019-2025
9.2.5 Southeast Asia Type I Hyperlipoproteinemia Drug Forecast 2019-2025
9.2.6 India Type I Hyperlipoproteinemia Drug Forecast 2019-2025
9.3 Type I Hyperlipoproteinemia Drug Market Trend (Product Type)
9.4 Type I Hyperlipoproteinemia Drug Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Type I Hyperlipoproteinemia Drug Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Type I Hyperlipoproteinemia Drug
Table Global Type I Hyperlipoproteinemia Drug Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Type I Hyperlipoproteinemia Drug Production Market Share by Types in 2018
Figure Alipogene Tiparvovec Product Picture
Figure CAT-2003 Product Picture
Figure ISIS-APOCIIIRx Product Picture
Figure Lomitapide Mesylate Product Picture
Figure Pradigastat Sodium Product Picture
Figure Others Product Picture
Table Global Type I Hyperlipoproteinemia Drug Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Type I Hyperlipoproteinemia Drug Consumption Market Share by Applications in 2018
Figure Hospital
Figure Clinic
Figure Others
Figure Global Type I Hyperlipoproteinemia Drug Revenue (Million USD) (2014-2025)
Figure Global Type I Hyperlipoproteinemia Drug Production (K Pcs) (2014-2025)
Figure North America Type I Hyperlipoproteinemia Drug Market Size (Million USD) (2014-2025)
Figure Europe Type I Hyperlipoproteinemia Drug Market Size (Million USD) (2014-2025)
Figure China Type I Hyperlipoproteinemia Drug Market Size (Million USD) (2014-2025)
Figure Japan Type I Hyperlipoproteinemia Drug Market Size (Million USD) (2014-2025)
Figure Southeast Asia Type I Hyperlipoproteinemia Drug Market Size (Million USD) (2014-2025)
Figure India Type I Hyperlipoproteinemia Drug Market Size (Million USD) (2014-2025)
Table Type I Hyperlipoproteinemia Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Type I Hyperlipoproteinemia Drug in 2018
Figure Manufacturing Process Analysis of Type I Hyperlipoproteinemia Drug
Figure Industry Chain Structure of Type I Hyperlipoproteinemia Drug
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Type I Hyperlipoproteinemia Drug Manufacturing Plants Distribution
Table Type I Hyperlipoproteinemia Drug Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Type I Hyperlipoproteinemia Drug Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Type I Hyperlipoproteinemia Drug Production (K Pcs) of Major Manufacturers (2014-2019)
Table Type I Hyperlipoproteinemia Drug Production Market Share of Major Manufacturers (2014-2019)
Figure Type I Hyperlipoproteinemia Drug Production Share by Manufacturers in 2018
Table Type I Hyperlipoproteinemia Drug Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Type I Hyperlipoproteinemia Drug Revenue Market Share of Major Manufacturers (2014-2019)
Figure Type I Hyperlipoproteinemia Drug Revenue Share by Manufacturers in 2018
Table Type I Hyperlipoproteinemia Drug Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Type I Hyperlipoproteinemia Drug Production by Regions 2014-2019 (K Pcs)
Table Global Type I Hyperlipoproteinemia Drug Production Market Share by Regions 2014-2019
Figure Global Type I Hyperlipoproteinemia Drug Production Market Share by Regions in 2018
Table Global Type I Hyperlipoproteinemia Drug Revenue by Regions 2014-2019 (Million USD)
Table Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Regions 2014-2019
Figure Global Type I Hyperlipoproteinemia Drug Revenue Market Share by Regions in 2018
Table Global Type I Hyperlipoproteinemia Drug Consumption by Regions 2014-2019 (K Pcs)
Table Global Type I Hyperlipoproteinemia Drug Consumption Market Share by Regions 2014-2019
Figure North America Type I Hyperlipoproteinemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure North America Type I Hyperlipoproteinemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table North America Type I Hyperlipoproteinemia Drug Production, Consumption Import and Export (K Pcs)
Figure Europe Type I Hyperlipoproteinemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Type I Hyperlipoproteinemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Type I Hyperlipoproteinemia Drug Production, Consumption Import and Export (K Pcs)
Figure China Type I Hyperlipoproteinemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure China Type I Hyperlipoproteinemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table China Type I Hyperlipoproteinemia Drug Production, Consumption Import and Export (K Pcs)
Figure Japan Type I Hyperlipoproteinemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Type I Hyperlipoproteinemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Type I Hyperlipoproteinemia Drug Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Type I Hyperlipoproteinemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Type I Hyperlipoproteinemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Type I Hyperlipoproteinemia Drug Production, Consumption Import and Export (K Pcs)
Figure India Type I Hyperlipoproteinemia Drug Production Growth Rate 2014-2019 (K Pcs)
Figure India Type I Hyperlipoproteinemia Drug Revenue Growth Rate 2014-2019 (Million USD)
Table India Type I Hyperlipoproteinemia Drug Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Type I Hyperlipoproteinemia Drug Market Share by Application (2014-2019)
Figure Global Value (Consumption) Type I Hyperlipoproteinemia Drug Market Share by Application (2014-2019)
Table Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
Table Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Introduction, Application and Specification
Table Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Growth Rate (2014-2019)
Table Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Market Share (2014-2019)
Figure Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Revenue Market Share (2014-2019)
Table Aegerion Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Main Business and Markets Served
Table Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
Table Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Introduction, Application and Specification
Table Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Growth Rate (2014-2019)
Table Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Market Share (2014-2019)
Figure Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Revenue Market Share (2014-2019)
Table Catabasis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Main Business and Markets Served
Table Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
Table Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Product Introduction, Application and Specification
Table Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Growth Rate (2014-2019)
Table Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Production Market Share (2014-2019)
Figure Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Revenue Market Share (2014-2019)
Table Isis Pharmaceuticals, Inc. Type I Hyperlipoproteinemia Drug Main Business and Markets Served
Table Novartis AG Type I Hyperlipoproteinemia Drug Production Sites and Area Served
Table Novartis AG Type I Hyperlipoproteinemia Drug Product Introduction, Application and Specification
Table Novartis AG Type I Hyperlipoproteinemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Novartis AG Type I Hyperlipoproteinemia Drug Production Growth Rate (2014-2019)
Table Novartis AG Type I Hyperlipoproteinemia Drug Production Market Share (2014-2019)
Figure Novartis AG Type I Hyperlipoproteinemia Drug Revenue Market Share (2014-2019)
Table Novartis AG Type I Hyperlipoproteinemia Drug Main Business and Markets Served
Table uniQure N.V. Type I Hyperlipoproteinemia Drug Production Sites and Area Served
Table uniQure N.V. Type I Hyperlipoproteinemia Drug Product Introduction, Application and Specification
Table uniQure N.V. Type I Hyperlipoproteinemia Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table uniQure N.V. Type I Hyperlipoproteinemia Drug Production Growth Rate (2014-2019)
Table uniQure N.V. Type I Hyperlipoproteinemia Drug Production Market Share (2014-2019)
Figure uniQure N.V. Type I Hyperlipoproteinemia Drug Revenue Market Share (2014-2019)
Table uniQure N.V. Type I Hyperlipoproteinemia Drug Main Business and Markets Served
Figure Global Type I Hyperlipoproteinemia Drug Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Type I Hyperlipoproteinemia Drug Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Type I Hyperlipoproteinemia Drug Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Type I Hyperlipoproteinemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Type I Hyperlipoproteinemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Type I Hyperlipoproteinemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Type I Hyperlipoproteinemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Type I Hyperlipoproteinemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Type I Hyperlipoproteinemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Type I Hyperlipoproteinemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Type I Hyperlipoproteinemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Type I Hyperlipoproteinemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Type I Hyperlipoproteinemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Type I Hyperlipoproteinemia Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Type I Hyperlipoproteinemia Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Type I Hyperlipoproteinemia Drug by Type (2019-2025)
Table Global Consumption (K Pcs) of Type I Hyperlipoproteinemia Drug by Application (2019-2025)
Table Type I Hyperlipoproteinemia Drug Distributors List
Table Type I Hyperlipoproteinemia Drug Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

Aegerion Pharmaceuticals, Inc.、Catabasis Pharmaceuticals, Inc.、Isis Pharmaceuticals, Inc.、Novartis AG、uniQure N.V.

★調査レポート[世界のI型高リポタンパク血症薬市場 2019年] (コード:DATA908B04842)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のI型高リポタンパク血症薬市場 2019年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆